Cargando…

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

BACKGROUND: About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a promising new target for antibody–drug conjugates (ADCs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Tinchon, Christoph, Petzer, Andreas, Balic, Marija, Heibl, Sonja, Schmitt, Clemens, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Singer, Christian Fridolin, Roitner, Florian, Hager, Christopher, Andel, Johannes, Hubalek, Michael, Knauer, Michael, Greil, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670265/ https://www.ncbi.nlm.nih.gov/pubmed/34906198 http://dx.doi.org/10.1186/s13058-021-01492-x

Ejemplares similares

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2021)

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group
por: Leisch, Michael, et al.
Publicado: (2022)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2022)

MBC and ECBL libraries: outstanding tools for drug discovery
por: Ginex, Tiziana, et al.
Publicado: (2023)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Correspondence: Confirmation of Uterotrophic Activity for 4-MBC in the Immature Rat
por: Ashby, J
Publicado: (2001)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Case report and literature review on a large MBC with ulceration
por: Luo, Qin-Qin, et al.
Publicado: (2023)

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
por: Rinnerthaler, Gabriel, et al.
Publicado: (2022)

Predicting Resistance by Mutagenesis: Lessons from 45 Years of MBC Resistance
por: Hawkins, Nichola J., et al.
Publicado: (2016)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Multi-Stress Induction of the Mycobacterium tuberculosis MbcTA Bactericidal Toxin-Antitoxin System
por: Ariyachaokun, Kanchiyaphat, et al.
Publicado: (2020)

Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT
por: Pleyer, Lisa, et al.
Publicado: (2023)

Screening the Toxicity of Selected Personal Care Products Using Embryo Bioassays: 4-MBC, Propylparaben and Triclocarban
por: Torres, Tiago, et al.
Publicado: (2016)

Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC
por: Parry, Marina
Publicado: (2018)

Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient – a case report
por: Ramaswamy, Rajkumar, et al.
Publicado: (2019)

The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against Staphylococcus aureus
por: Parvekar, Prashik, et al.
Publicado: (2020)

P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)
por: Ludwig, Heinz, et al.
Publicado: (2023)

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial
por: Egle, Alexander, et al.
Publicado: (2019)

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
por: Gampenrieder, S.P., et al.
Publicado: (2022)

A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC)
por: Yu, Xing-Fei, et al.
Publicado: (2015)

Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience †
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
por: Bensalem, A, et al.
Publicado: (2005)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

The Foodborne Strain Lactobacillus fermentum MBC2 Triggers pept-1-Dependent Pro-Longevity Effects in Caenorhabditis elegans
por: Schifano, Emily, et al.
Publicado: (2019)

The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
por: Pérol, David, et al.
Publicado: (2019)

The results of clinician-focused implementation strategies on uptake and outcomes of Measurement-Based Care (MBC) in general mental health care
por: van Sonsbeek, Maartje A. M. S., et al.
Publicado: (2023)

Analysis of β-tubulin-carbendazim interaction reveals that binding site for MBC fungicides does not include residues involved in fungicide resistance
por: Vela-Corcía, David, et al.
Publicado: (2018)

Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) for Twelve Antimicrobials (Biocides and Antibiotics) in Eight Strains of Listeria monocytogenes
por: Rodríguez-Melcón, Cristina, et al.
Publicado: (2021)

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
por: Tang, Yu, et al.
Publicado: (2022)

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
por: Trevisan, B., et al.
Publicado: (2023)

Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg—a report from the AGMT COVID-19 Registry
por: Huemer, Florian, et al.
Publicado: (2021)

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Implementing measurement-based care (iMBC) for depression in community mental health: a dynamic cluster randomized trial study protocol
por: Lewis, Cara C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_11odaplmjbtsi49pkn2jikr2ml